Why is tacrolimus often first-line in transplantation?

Randomized trials and meta-analysis show lower acute rejection and graft loss versus ciclosporin, which is why it is commonly preferred.

Why does tacrolimus need blood-level monitoring?

It has a narrow therapeutic index, so whole-blood trough levels are measured to keep it effective while limiting nephrotoxicity and other harms.

What are tacrolimus's main risks?

Kidney and nerve toxicity, new-onset diabetes, and the class-wide increased risk of infection and malignancy including lymphoma.

Are tacrolimus formulations interchangeable?

No. Immediate-release and extended-release products are not milligram-for-milligram interchangeable and switching requires medical supervision and re-monitoring.

EMA-approved

Tacrolimus — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Tacrolimus is a peptide catalogued under Cyclic & Antimicrobial. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Tacrolimus?

Tacrolimus (FK506) is a macrolide calcineurin inhibitor produced by the bacterium Streptomyces tsukubaensis and is more potent than ciclosporin.

It is approved by the FDA and EMA to prevent rejection of kidney, liver and heart transplants, and is also marketed as a topical agent for atopic dermatitis.

It is widely used first-line in transplantation, supported by multiple randomized controlled trials.

How does Tacrolimus work?

Tacrolimus binds FK506-binding protein-12 (FKBP12), and the resulting complex inhibits calcineurin.

This prevents dephosphorylation of NFAT and suppresses interleukin-2-driven T-cell activation.

What does the research say about Tacrolimus?

A meta-analysis of randomized trials found tacrolimus reduced acute rejection and graft loss compared with ciclosporin in kidney-transplant recipients. ^[5]
In a European renal-transplant trial, tacrolimus lowered the incidence and severity of acute rejection versus ciclosporin. ^[2]
In the Symphony trial, a low-dose tacrolimus regimen produced the best renal function and graft survival among the compared regimens. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation — The U.S. Multicenter FK506 Liver Study Group, The New England Journal of Medicine 1994. (Randomized controlled trial)
[2] Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group — Mayer AD et al., Transplantation 1997. (Randomized controlled trial)
[3] A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group — Pirsch JD et al., Transplantation 1997. (Randomized controlled trial)
[4] Reduced exposure to calcineurin inhibitors in renal transplantation — Ekberg H et al., The New England Journal of Medicine 2007. (Randomized controlled trial (Symphony))
[5] Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta regression of randomised trial data — Webster AC et al., BMJ 2005. (Meta-analysis of randomized trials)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

This is context only and not dosing guidance: tacrolimus dosing is highly individualized and adjusted to whole-blood trough targets that change with organ type and time after transplant.

Therapeutic drug monitoring is essential, and immediate-release and extended-release formulations are not milligram-for-milligram interchangeable.

Side effects & safety profile

Like all immunosuppressants, tacrolimus increases the risk of serious and opportunistic infections and of malignancy, including lymphoma / post-transplant lymphoproliferative disorder and skin cancer, reflecting the class boxed warning.

Drug-specific toxicities include nephrotoxicity, neurotoxicity (tremor, headache) and new-onset diabetes after transplantation.

Its narrow therapeutic index mandates whole-blood trough level monitoring.

Stacking & combinations

In maintenance transplant regimens tacrolimus is usually combined with corticosteroids and mycophenolate as triple immunosuppressive therapy.

Finding Tacrolimus vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Both are calcineurin inhibitors, but tacrolimus is a macrolide that binds FKBP12, is more potent, and in trials generally causes less acute rejection, at the cost of more post-transplant diabetes.

References

[1] A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation — The U.S. Multicenter FK506 Liver Study Group, The New England Journal of Medicine 1994. PMID: 7523946. View sourceStudy: Randomized controlled trialTacrolimus reduced acute and refractory rejection versus ciclosporin in liver-transplant recipients.
[2] Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group — Mayer AD et al., Transplantation 1997. PMID: 9275110. View sourceStudy: Randomized controlled trialTacrolimus lowered the incidence and severity of acute renal-allograft rejection compared with ciclosporin.
[3] A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group — Pirsch JD et al., Transplantation 1997. PMID: 9112351. View sourceStudy: Randomized controlled trialTacrolimus reduced acute rejection versus ciclosporin after cadaveric kidney transplantation, with more post-transplant diabetes.
[4] Reduced exposure to calcineurin inhibitors in renal transplantation — Ekberg H et al., The New England Journal of Medicine 2007. PMID: 18094377. View sourceStudy: Randomized controlled trial (Symphony)A low-dose tacrolimus regimen gave the best renal function, graft survival and lowest acute rejection among compared regimens.
[5] Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta regression of randomised trial data — Webster AC et al., BMJ 2005. PMID: 16157605. View sourceStudy: Meta-analysis of randomized trialsTacrolimus reduced acute rejection and graft loss but increased new-onset diabetes compared with ciclosporin.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.